Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18086980 | 1.00 | ELANE (0.79) | ELANE | |
| SCHEMBL124800 | 1.00 | ELANE (0.79) | ELANE | |
| SCHEMBL18086836 | 0.92 | ELANE (0.78) | ELANE | |
| SCHEMBL122654 | 0.91 | ELANE (0.70) | ELANE | |
| SCHEMBL3722083 | 0.91 | ELANE (0.70) | ELANE | |
| SCHEMBL1154970 | 0.89 | ELANE (0.66) | ELANE | |
| SCHEMBL3663656 | 0.89 | ELANE (1.00) | ELANE | |
| SCHEMBL29443698 | 0.89 | ELANE (1.00) | ELANE | |
| SCHEMBL121431 | 0.89 | ELANE (1.00) | ELANE | |
| SCHEMBL29359628 | 0.89 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271337-B1 | PROCESS FOR THE PREPARATION OF (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUORMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDIN-5-CARBONITRIL | PH PHARMA CO LTD (KR) | 2021-03-03 | — | — | EP | disclosed |
| EP-3271337-B1 | PROCESS FOR THE PREPARATION OF (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUORMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDIN-5-CARBONITRIL | PH PHARMA CO LTD (KR) | 2021-03-03 | — | — | EP | disclosed |
| US-10676443-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | PH PHARMA CO., LTD. (KR) | 2020-06-09 | — | — | US | disclosed |
| US-20190248750-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | PH PHARMA CO., LTD. (KR) | 2019-08-15 | — | — | US | disclosed |
| US-10316001-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrohydro pyrimidine-5-carbonitrile | PH PHARMA CO., LTD. (KR) | 2019-06-11 | — | — | US | disclosed |
| US-20180072685-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | pH Pharma, Ltd. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180072685-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | pH Pharma, Ltd. (KR) | 2018-03-15 | — | — | US | disclosed |
| WO-2016146607-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | WO | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072685-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | PFAS, CYP2S1, DPYD | ELANE 4665/4885 |
| US-10316001-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrohydro pyrimidine-5-carbonitrile | TYMS, TPMT, CTPS1 | ELANE 4659/4885 |
| US-20190248750-A1 | METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE | CYP2S1, PFAS, DPYD | ELANE 4588/4885 |
| US-10676443-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | CYP2S1, PFAS, DPYD | ELANE 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.